These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 11103436)

  • 21. The Fas signalling pathway and its role in the pathogenesis of cancer.
    Houston A; O'Connell J
    Curr Opin Pharmacol; 2004 Aug; 4(4):321-6. PubMed ID: 15251123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of Fas (CD95)-induced apoptotic and necrotic cell death by reactive oxygen species in macrophages.
    Medan D; Wang L; Toledo D; Lu B; Stehlik C; Jiang BH; Shi X; Rojanasakul Y
    J Cell Physiol; 2005 Apr; 203(1):78-84. PubMed ID: 15368542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Graft vs host disease].
    Moalic V; Ferec C
    Pathol Biol (Paris); 2006 May; 54(5):304-8. PubMed ID: 16530350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of apoptosis in thyroid disease.
    Tsatsoulis A
    Minerva Med; 2002 Jun; 93(3):169-80. PubMed ID: 12094148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BAFF and LPS cooperate to induce B cells to become susceptible to CD95/Fas-mediated cell death.
    Acosta-Rodríguez EV; Craxton A; Hendricks DW; Merino MC; Montes CL; Clark EA; Gruppi A
    Eur J Immunol; 2007 Apr; 37(4):990-1000. PubMed ID: 17357108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome).
    Paquet P; Piérard GE; Quatresooz P
    Int Arch Allergy Immunol; 2005 Mar; 136(3):205-16. PubMed ID: 15713983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of Fas and FasL as mediators of anticancer chemotherapy.
    Poulaki V; Mitsiades CS; Mitsiades N
    Drug Resist Updat; 2001 Aug; 4(4):233-42. PubMed ID: 11991678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease.
    Georgantas RW; Bohana-Kashtan O; Civin CI
    Transplantation; 2006 Aug; 82(4):471-8. PubMed ID: 16926590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell death modulation by intravenous immunoglobulin.
    von Gunten S; Simon HU
    J Clin Immunol; 2010 May; 30 Suppl 1():S24-30. PubMed ID: 20405180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxic epidermal necrolysis: review of pathogenesis and management.
    Downey A; Jackson C; Harun N; Cooper A
    J Am Acad Dermatol; 2012 Jun; 66(6):995-1003. PubMed ID: 22169256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Graft-versus-host reaction manifested as toxic epidermal necrolysis in a patient with acute leukemia.
    Berkel AI; Tinaztepe K
    Turk J Pediatr; 1981; 23(1):37-41. PubMed ID: 7200649
    [No Abstract]   [Full Text] [Related]  

  • 33. Inhibition of Fas death pathway in cytotoxic T cells: an approach to prevent graft-versus-host disease.
    Paillard F
    Hum Gene Ther; 1998 Jul; 9(11):1528-9. PubMed ID: 9694151
    [No Abstract]   [Full Text] [Related]  

  • 34. Toxic epidermal necrolysis and homologous disease in hamsters.
    Billingham RE; Streilein JW
    Arch Dermatol; 1968 Nov; 98(5):528-39. PubMed ID: 5684230
    [No Abstract]   [Full Text] [Related]  

  • 35. Responsiveness to i.v. immunoglobulin therapy in patients with toxic epidermal necrolysis: A novel pharmaco-immunogenetic concept.
    Borilova Linhartova P; Gachova D; Lipovy B
    J Dermatol; 2020 Nov; 47(11):1236-1248. PubMed ID: 32935409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Case of toxic epidermal necrolysis in a 10-year-old child].
    Prikhodzhenko EM; Peshiĭ MM; Vasilenko OO; Baraban MS; Ivanova IS
    Pediatr Akus Ginekol; 1973; 6():30-1. PubMed ID: 4786367
    [No Abstract]   [Full Text] [Related]  

  • 37. [Picture of the month. Toxic epidermal necrolysis].
    Weismann K
    Ugeskr Laeger; 2000 Mar; 162(11):1568. PubMed ID: 10868114
    [No Abstract]   [Full Text] [Related]  

  • 38. Therapeutic opportunities from the pharmacological manipulation of the Fas system.
    Maggi CA
    Pharmacol Res; 1998 Jul; 38(1):1-34. PubMed ID: 9697151
    [No Abstract]   [Full Text] [Related]  

  • 39. The complex web of FasL: cell type-specific roles in affecting and controlling acute graft-vs-host disease.
    Choy JC
    J Leukoc Biol; 2023 Sep; 114(3):202-204. PubMed ID: 37431614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toxic Epidermal Necrolysis Managed with Immunoglobulin.
    Choudhury GD; Agarwal V
    Med J Armed Forces India; 2008 Jul; 64(3):272-3. PubMed ID: 27408164
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.